Skip to main content
. 2014 Mar 10;9(3):e90119. doi: 10.1371/journal.pone.0090119

Table 1. Patient characteristics N (%) and hazard ratios (HR) together with 95%-confidence intervals (CI) for factors.

Factor Model 1: HR (CI) Model 2: HR (CI)
Dialysis modality1 HD PD All
8273 (68) 3822 (32) 12095 (100) .89 (.84–.93) .87 (.83–.92)**
Cohort ** **
1990–94 1099 (13) 748 (20) 1847 (15) 1 (ref) 1 (ref)
1995–99 1877 (23) 792 (21) 2669 (22) .85 (.79–.91)** .86 (.80–.93)*
2000–04 2482 (30) 1022 (27) 3504 (29) .7 (.65–.75)** .76 (.70–.81)**
2005–10 2815 (34) 1260 (33) 4075 (34) .59 (.54–.64)** .66 (.61–.72)**
Age **
0–59 2961 (36) 1962 (51) 4923 (41) 1 (ref)
60–69 2158 (26) 975 (26) 3133 (26) 1.88 (1.76–2.01)**
70–79 2337 (28) 697 (18) 3034 (25) 2.7 (2.52–2.89)**
> = 80 817 (10) 188 (5) 1005 (8) 3.62 (3.3–3.97)**
Age> = 65 4335 (52) 1344 (35) 5679 (47) 2.09 (1.99–2.20)**
Female Sex 3045 (37) 1449 (38) 4494 (37) .98 (.94–1.03) .99 (.94–1.04)
Renal Diagnosis **
Unknown 1931 (23) 852 (22) 2783 (23) 1 (ref)
Glomerulonephritis (GN) 846 (10) 590 (15) 1436 (12) .76 (.69–.84)**
Chronic interstitial (CIN) 996 (12) 390 (10) 1386 (12) .92 (.85–1)
Polycystic 504 (6) 356 (9) 860 (7) .73 (.66–.82)**
Hypertensive 961 (12) 430 (11) 1391 (11) .99 (.91–1.07)
Type 1 DM 824 (10) 632 (17) 1456 (12) 1.57 (1.44–1.71)**
Type 2 DM 998 (12) 284 (7) 1282 (11) 1.41 (1.30–1.52)**
Renal Cancer 136 (2) 19 (0.5) 155 (1) 1.13 (.90–1.42)
Myeloma 207 (3) 32 (0.8) 239 (2) 2.08 (1.75–2.47)**
Amyloidosis 71 (0.9) 41 (1) 112 (0.9) 2.11 (1.64–2.73)**
Systemic GN 97 (1) 52 (1) 149 (1) .98 (.76–1.26)
Vasculitis 377 (5) 70 (2) 447 (4) .83 (.72–.96)*
HUS/TTP2 40 (0.5) 15 (0.4) 55 (0.5) .49 (.29–.81)*
Other 285 (3) 59 (2) 344 (3) .97 (.83–1.13)
DM diagnosis 1822 (22) 916 (24) 2738 (23) 1.51 (1.43–1.6)**
Comorbidity ** **
0 2837 (34) 1941 (51) 4778 (40) 1 (ref) 1 (ref)
1–2 3623 (44) 1423 (37) 5046 (42) 1.6 (1.51–1.69)** 1.69 (1.6–1.79)**
>2 1813 (22) 458 (12) 2271 (19) 2.3 (2.14–2.46)** 2.52 (2.35–2.7)**
ESRD Initiation ** **
Early & Routine 2145 (26) 1419 (37) 3564 (29) .91 (.86–.96)* .89 (.84–.94)**
Late & Acute 2138 (26) 648 (17) 2786 (23) 1.1 (1.03–1.16)* 1.12 (1.05–1.19)**
Other 3990 (48) 1755 (46) 5745 (47) 1 (ref) 1 (ref)

Corresponding significant p-values are presented as.

*: p<.05;

**:p<.001.

For definition of models see methods section.

1

:HD is the reference category;

2

: Hemolytic Uremic Syndrome/ThrombocoticThrombocytopenic Purpura.